A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure
30 August 2024 (08:00 - 17:30)
Organised by: 

About the speaker

Tufts Medical Center, Inc., Boston (United States of America)
9 More presentations in this session

Doctor D. Lindholm (Norrtalje, SE)
Access the full session
The Event
ESC Congress 2024
30 August - 2 September 2024
You may be interested in
Congress Presentation
Congress Presentation


